Financial Performance - For the six months ended June 30, 2023, the company's revenue was RMB 370,467 thousand, a decrease of 1.1% compared to RMB 374,742 thousand in the same period of 2022 [47]. - Gross profit for the same period was RMB 69,950 thousand, reflecting a decline of 16.3% from RMB 83,571 thousand year-over-year [47]. - Profit attributable to owners of the company for the six months was RMB 24,263 thousand, down 24.6% from RMB 32,173 thousand in the prior year [47]. - Basic and diluted earnings per share decreased by 20.0% to RMB 0.04 from RMB 0.05 in the previous year [47]. - The consolidated revenue for the six months ended June 30, 2023, was RMB 370.5 million, a decrease of 1.1% from RMB 374.7 million for the same period in 2022 [73]. - The company reported a net profit of RMB 24.5 million for the six months ended June 30, 2023, down 24.5% from RMB 32.5 million in the same period of 2022 [177]. Cash Flow and Financing - As of June 30, 2023, the financing activities generated cash of RMB 9.5 million, compared to cash used of RMB 32.5 million for the same period in 2022, primarily due to new borrowings of RMB 28.1 million [2]. - The net increase in cash and cash equivalents for the period was RMB 18.1 million, compared to RMB 3.7 million in the previous year, indicating improved liquidity [168]. - The company has not utilized the additional loan facility of RMB 60 million obtained from a bank as of the reporting date [179]. - The company aims to use 15% of the funds (RMB 39.8 million) for repaying general borrowings, particularly for loans totaling RMB 63.0 million from two banks [41]. Assets and Liabilities - The total assets as of June 30, 2023, were RMB 957,913,000, compared to RMB 935,038,000 as of December 31, 2022, reflecting a growth of 2.4% [77]. - The company's current liabilities exceeded current assets by RMB 20.6 million as of June 30, 2023, with cash and cash equivalents amounting to RMB 274.35 million [148]. - Total liabilities increased from RMB 380.37 million as of December 31, 2022, to RMB 393.99 million as of June 30, 2023 [147]. - Borrowings increased from RMB 141.0 million as of December 31, 2022, to RMB 169.1 million as of June 30, 2023, an increase of RMB 28.1 million due to new borrowings during the reporting period [164]. Corporate Governance - The company has complied with all applicable corporate governance codes during the reporting period, with no significant changes in the nature of its business [18]. - The audit committee consists of three independent non-executive directors, ensuring effective oversight of financial reporting [20]. - The company is committed to enhancing its corporate governance in accordance with the listing rules [30]. Employee and Administrative Costs - The total number of employees as of June 30, 2023, was approximately 1,886, an increase from 1,877 as of June 30, 2022 [24]. - Employee costs for the six months ended June 30, 2023, were approximately RMB 107.4 million, compared to RMB 90.7 million for the same period in 2022, representing an increase of about 18.5% [24]. - Administrative expenses increased by 4.9% to RMB 36.9 million for the six months ended June 30, 2023, from RMB 35.2 million for the same period in 2022, mainly due to increased employee benefits [109]. Investment Activities - The net cash used in investment activities increased from RMB 4.6 million for the six months ended June 30, 2022, to RMB 37.8 million for the same period in 2023, primarily due to increased payments for property, plant, and equipment by RMB 33.2 million [34]. - The company plans to allocate 29.5% of the raised funds (RMB 78.0 million) for the expansion of its first-phase building [41]. - 26.1% of the funds (RMB 69.2 million) will be used for acquiring hospitals to expand the company's business [41]. Market and Operational Insights - The number of outpatient visits and inpatient admissions increased due to improved diagnostic and treatment capabilities, as well as expanded medical service offerings [74]. - The number of inpatient visits increased to 27,620 for the six months ended June 30, 2023, representing an 11.09% increase from 24,863 in the same period of 2022 [97]. - The average cost per inpatient decreased to RMB 6,409.5, down 12.07% from RMB 7,289.2 in the same period of 2022 [97]. - The company aims to enhance core competitiveness and brand influence by expanding service types and improving service chains [72]. Revenue Breakdown - Revenue from treatment and comprehensive medical services was RMB 228,587 thousand, down from RMB 238,292 thousand in the same period last year [62]. - Pharmaceutical sales increased to RMB 141,880 thousand from RMB 136,450 thousand year-over-year [62]. - Outpatient medical service revenue decreased by 0.04% to RMB 193.4 million for the six months ended June 30, 2023, compared to RMB 193.5 million for the same period in 2022, primarily due to a reduction in average outpatient fees [105]. - Inpatient medical service revenue decreased by 2.3% to RMB 177.0 million for the six months ended June 30, 2023, compared to RMB 181.2 million for the same period in 2022, primarily due to a reduction in average inpatient fees [130].
宏力医疗管理(09906) - 2023 - 中期业绩